In Q2 2025, Cormorant Asset Management held 38 positions worth $1.2B. They initiated 1 new position and exited 57. Their largest holding was MLTX ($400.9M). Portfolio value shrank -0.9% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q2 2025?
Cormorant Asset Management held 38 biotech stocks in their 13F portfolio in Q2 2025. Their top positions include MLTX, EYPT, BBIO, PRAX, EWTX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q2 2025?
Cormorant Asset Management's tracked biotech portfolio was worth $1.2B across 38 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q2 2025?
Cormorant Asset Management initiated 1 new position in Q2 2025, including VRNA. They also increased 5 existing positions.
What did Cormorant Asset Management sell in Q2 2025?
Cormorant Asset Management fully exited 57 positions in Q2 2025, including ALXO, CMPS, CGEM, IDYA, OLMA and 52 more. They also trimmed 16 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Managementportfolio →